O	0	10	Prevention
O	11	13	of
B-condition	14	25	anastrozole
I-condition	26	33	induced
I-condition	34	38	bone
I-condition	39	43	loss
O	44	48	with
O	49	56	monthly
O	57	61	oral
B-intervention	62	73	ibandronate
O	73	74	:
O	75	80	Final
O	81	82	5
O	83	87	year
O	88	95	results
O	96	100	from
O	101	104	the
O	105	111	ARIBON
O	112	117	trial
O	117	118	.

O	119	122	The
O	123	129	ARIBON
O	130	135	trial
O	136	138	is
O	139	140	a
O	141	147	double
O	148	153	blind
O	153	154	,
O	155	165	randomised
O	165	166	,
O	167	174	placebo
O	175	185	controlled
O	186	191	study
O	192	200	designed
O	201	203	to
O	204	212	evaluate
O	213	216	the
O	217	223	impact
O	224	226	of
O	227	238	ibandronate
O	239	241	on
O	242	246	bone
O	247	254	mineral
O	255	262	density
O	263	264	(
O	264	267	BMD
O	267	268	)
O	269	271	in
O	272	277	women
O	278	284	taking
O	285	296	anastrozole
O	297	300	for
O	301	309	adjuvant
O	310	319	treatment
O	320	322	of
O	323	329	breast
O	330	336	cancer
O	336	337	.

B-total-participants	338	341	131
B-eligibility	342	356	postmenopausal
I-eligibility	357	362	women
I-eligibility	363	367	with
I-eligibility	368	373	early
I-eligibility	374	380	breast
I-eligibility	381	387	cancer
O	388	392	were
O	393	402	recruited
O	403	405	to
O	406	409	the
O	410	415	study
O	415	416	.

O	417	419	Of
O	420	425	these
O	425	426	,
B-total-participants	427	429	13
O	430	433	had
O	434	446	osteoporosis
O	446	447	,
B-total-participants	448	450	50
O	451	461	osteopenia
O	462	465	and
B-total-participants	466	468	68
O	469	475	normal
O	476	479	BMD
O	479	480	.

O	481	489	Patients
O	490	494	with
O	495	507	osteoporosis
O	508	510	at
O	511	519	baseline
O	520	524	were
O	525	532	treated
O	533	537	with
O	538	545	monthly
O	546	550	oral
O	551	562	ibandronate
O	563	566	150
O	566	567	Ã‚
O	568	570	mg
O	571	574	for
O	575	576	5
O	577	582	years
O	582	583	;
O	584	594	osteopenic
O	595	603	patients
O	604	608	were
O	609	619	randomised
O	620	622	to
O	623	630	receive
O	631	637	either
O	638	649	ibandronate
O	650	652	or
B-control	653	660	placebo
O	661	664	for
O	665	668	two
O	669	674	years
O	675	678	and
O	679	686	offered
O	687	691	open
O	692	697	label
O	698	709	ibandronate
O	710	719	depending
O	720	724	upon
O	725	728	the
O	729	736	results
O	737	739	of
O	740	745	their
O	746	747	2
O	747	748	-
O	748	752	year
O	753	756	BMD
O	757	763	result
O	763	764	.

O	765	767	Of
O	768	771	the
B-intervention-participants	772	774	20
O	775	783	patients
O	784	788	with
O	789	799	osteopenia
O	800	803	who
O	804	808	were
O	809	819	randomised
O	820	822	to
O	823	834	ibandronate
O	835	838	and
O	839	848	evaluable
O	849	851	at
O	852	855	the
O	856	857	2
O	858	862	year
O	863	868	visit
O	868	869	,
O	870	872	17
O	872	873	/
O	873	875	20
O	876	880	were
O	881	884	not
O	885	892	offered
O	893	894	a
O	895	909	bisphosphonate
O	910	913	and
O	914	917	the
O	918	930	improvements
O	931	933	in
B-outcome	934	937	BMD
O	938	945	accrued
O	946	952	during
O	953	956	the
O	957	962	first
O	963	964	2
O	965	970	years
O	971	975	were
O	976	980	lost
O	981	985	both
O	986	988	at
O	989	992	the
O	993	995	LS
O	996	997	(
O	997	998	-
O	998	999	3
O	999	1000	.
O	1000	1002	21
O	1002	1003	%
O	1003	1004	)
O	1005	1008	and
O	1009	1011	TH
O	1012	1013	(
O	1013	1014	-
O	1014	1015	5
O	1015	1016	.
O	1016	1017	0
O	1017	1018	%
O	1018	1019	)
O	1019	1020	.

O	1021	1023	Of
O	1024	1027	the
B-control-participants	1028	1030	16
O	1031	1039	patients
O	1040	1050	randomised
O	1051	1053	to
O	1054	1061	placebo
O	1062	1063	8
O	1063	1064	/
O	1064	1066	16
O	1067	1071	with
O	1072	1076	high
O	1077	1082	rates
O	1083	1085	of
O	1086	1090	bone
O	1091	1095	loss
O	1096	1102	during
O	1103	1108	years
O	1109	1110	0
O	1110	1111	-
O	1111	1112	2
O	1113	1121	received
O	1122	1133	ibandronate
O	1134	1138	over
O	1139	1142	the
O	1143	1147	next
O	1148	1149	3
O	1150	1155	years
O	1156	1160	with
B-outcome	1161	1173	improvements
I-outcome	1174	1176	in
I-outcome	1177	1180	BMD
O	1181	1183	of
O	1184	1185	+
O	1185	1186	5
O	1186	1187	.
O	1187	1189	01
O	1190	1193	and
O	1194	1195	+
O	1195	1196	1
O	1196	1197	.
O	1197	1199	19
O	1200	1202	at
O	1203	1206	the
O	1207	1209	LS
O	1210	1213	and
O	1214	1216	TH
O	1217	1229	respectively
O	1229	1230	.

O	1231	1234	The
B-control-participants	1235	1236	8
O	1237	1245	patients
O	1246	1249	who
O	1250	1254	were
O	1255	1258	not
O	1259	1266	offered
O	1267	1268	a
O	1269	1283	bisphosphonate
O	1284	1295	experienced
O	1296	1306	relatively
O	1307	1313	little
B-outcome	1314	1320	change
I-outcome	1321	1323	in
I-outcome	1324	1327	BMD
O	1328	1338	throughout
O	1339	1342	the
O	1343	1344	5
O	1345	1350	years
O	1351	1353	of
O	1354	1357	the
O	1358	1363	study
O	1364	1365	(
O	1365	1367	LS
O	1368	1369	+
O	1369	1370	0
O	1370	1371	.
O	1371	1373	15
O	1373	1374	%
O	1374	1375	,
O	1376	1378	TH
O	1379	1380	-
O	1380	1381	2
O	1381	1382	.
O	1382	1384	72
O	1384	1385	%
O	1385	1386	)
O	1386	1387	.

B-outcome	1388	1391	BMD
I-outcome	1392	1401	increased
O	1402	1410	steadily
O	1411	1413	in
O	1414	1417	the
O	1418	1419	9
O	1419	1420	/
O	1420	1422	13
O	1423	1431	patients
O	1432	1441	initially
O	1442	1452	identified
O	1453	1455	as
O	1456	1462	having
O	1463	1475	osteoporosis
O	1476	1477	(
O	1477	1479	LS
O	1480	1481	+
O	1481	1482	9
O	1482	1483	.
O	1483	1485	65
O	1485	1486	%
O	1486	1487	,
O	1488	1490	TH
O	1491	1492	+
O	1492	1493	2
O	1493	1494	.
O	1494	1496	72
O	1496	1497	%
O	1497	1498	)
O	1498	1499	.

O	1500	1507	Monthly
O	1508	1512	oral
O	1513	1524	ibandronate
O	1525	1533	provides
O	1534	1536	an
O	1537	1543	option
O	1544	1546	to
O	1547	1557	clinicians
O	1558	1569	considering
O	1570	1573	use
O	1574	1576	of
O	1577	1578	a
O	1579	1593	bisphosphonate
O	1594	1596	to
O	1597	1604	prevent
O	1605	1609	bone
O	1610	1614	loss
O	1615	1621	during
O	1622	1631	aromatase
O	1632	1641	inhibitor
O	1642	1649	therapy
O	1649	1650	.
